Global Cancer Immunotherapy 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR072419416

Publication Date:

July 31, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Cancer Immunotherapy market size was valued at USD 50920 million in 2023 and is forecast to a readjusted size of USD 173500 million by 2030 with a CAGR of 19.1% during review period.
Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report includes an overview of the development of the Cancer Immunotherapy industry chain, the market status of Lung Cancer (Immune Checkpoint Inhibitors, Immune System Modulators), Breast Cancer (Immune Checkpoint Inhibitors, Immune System Modulators), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Cancer Immunotherapy.
Regionally, the report analyzes the Cancer Immunotherapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Cancer Immunotherapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Cancer Immunotherapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Cancer Immunotherapy industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Immune Checkpoint Inhibitors, Immune System Modulators).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Cancer Immunotherapy market.
Regional Analysis: The report involves examining the Cancer Immunotherapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Cancer Immunotherapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Cancer Immunotherapy:
Company Analysis: Report covers individual Cancer Immunotherapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cancer Immunotherapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer, Breast Cancer).
Technology Analysis: Report covers specific technologies relevant to Cancer Immunotherapy. It assesses the current state, advancements, and potential future developments in Cancer Immunotherapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Cancer Immunotherapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Cancer Immunotherapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
麻豆原创 segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Others
麻豆原创 segment by players, this report covers
Amgen
AstraZeneca
Roche
Bayer
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Cancer Immunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cancer Immunotherapy, with revenue, gross margin and global market share of Cancer Immunotherapy from 2019 to 2024.
Chapter 3, the Cancer Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Cancer Immunotherapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Immunotherapy.
Chapter 13, to describe Cancer Immunotherapy research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Cancer Immunotherapy
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Cancer Immunotherapy by Type
1.3.1 Overview: Global Cancer Immunotherapy 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Cancer Immunotherapy Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Immune Checkpoint Inhibitors
1.3.4 Immune System Modulators
1.3.5 Cancer Vaccines
1.4 Global Cancer Immunotherapy 麻豆原创 by Application
1.4.1 Overview: Global Cancer Immunotherapy 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Lung Cancer
1.4.3 Breast Cancer
1.4.4 Colorectal Cancer
1.4.5 Melanoma
1.4.6 Prostate Cancer
1.4.7 Others
1.5 Global Cancer Immunotherapy 麻豆原创 Size & Forecast
1.6 Global Cancer Immunotherapy 麻豆原创 Size and Forecast by Region
1.6.1 Global Cancer Immunotherapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Cancer Immunotherapy 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Cancer Immunotherapy 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Cancer Immunotherapy 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Cancer Immunotherapy 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Cancer Immunotherapy 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Cancer Immunotherapy 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Cancer Immunotherapy Product and Solutions
2.1.4 Amgen Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Amgen Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Cancer Immunotherapy Product and Solutions
2.2.4 AstraZeneca Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Cancer Immunotherapy Product and Solutions
2.3.4 Roche Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Roche Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Cancer Immunotherapy Product and Solutions
2.4.4 Bayer Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Bayer Recent Developments and Future Plans
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb Cancer Immunotherapy Product and Solutions
2.5.4 Bristol-Myers Squibb Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Cancer Immunotherapy Product and Solutions
2.6.4 Eli Lilly Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Eli Lilly Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Cancer Immunotherapy Product and Solutions
2.7.4 Merck Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Merck Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Cancer Immunotherapy Product and Solutions
2.8.4 Novartis Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Cancer Immunotherapy Product and Solutions
2.9.4 Pfizer Cancer Immunotherapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Pfizer Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Cancer Immunotherapy Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Cancer Immunotherapy by Company Revenue
3.2.2 Top 3 Cancer Immunotherapy Players 麻豆原创 Share in 2023
3.2.3 Top 6 Cancer Immunotherapy Players 麻豆原创 Share in 2023
3.3 Cancer Immunotherapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 Cancer Immunotherapy 麻豆原创: Region Footprint
3.3.2 Cancer Immunotherapy 麻豆原创: Company Product Type Footprint
3.3.3 Cancer Immunotherapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Cancer Immunotherapy Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Cancer Immunotherapy 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Cancer Immunotherapy Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Cancer Immunotherapy 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Cancer Immunotherapy Consumption Value by Type (2019-2030)
6.2 North America Cancer Immunotherapy Consumption Value by Application (2019-2030)
6.3 North America Cancer Immunotherapy 麻豆原创 Size by Country
6.3.1 North America Cancer Immunotherapy Consumption Value by Country (2019-2030)
6.3.2 United States Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Cancer Immunotherapy Consumption Value by Type (2019-2030)
7.2 Europe Cancer Immunotherapy Consumption Value by Application (2019-2030)
7.3 Europe Cancer Immunotherapy 麻豆原创 Size by Country
7.3.1 Europe Cancer Immunotherapy Consumption Value by Country (2019-2030)
7.3.2 Germany Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Cancer Immunotherapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Cancer Immunotherapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Cancer Immunotherapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific Cancer Immunotherapy Consumption Value by Region (2019-2030)
8.3.2 China Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Cancer Immunotherapy Consumption Value by Type (2019-2030)
9.2 South America Cancer Immunotherapy Consumption Value by Application (2019-2030)
9.3 South America Cancer Immunotherapy 麻豆原创 Size by Country
9.3.1 South America Cancer Immunotherapy Consumption Value by Country (2019-2030)
9.3.2 Brazil Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Cancer Immunotherapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Cancer Immunotherapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Cancer Immunotherapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa Cancer Immunotherapy Consumption Value by Country (2019-2030)
10.3.2 Turkey Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Cancer Immunotherapy 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Cancer Immunotherapy 麻豆原创 Drivers
11.2 Cancer Immunotherapy 麻豆原创 Restraints
11.3 Cancer Immunotherapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Cancer Immunotherapy Industry Chain
12.2 Cancer Immunotherapy Upstream Analysis
12.3 Cancer Immunotherapy Midstream Analysis
12.4 Cancer Immunotherapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Amgen
AstraZeneca
Roche
Bayer
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.